Elizabeth Klumpp - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Elizabeth Klumpp's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Elizabeth Klumpp
Verified
Group Editorial Director, Oncology, Haymarket Media
Pennsylvania
Beats
fitness and wellness
MUSICAL ARTIST / YOUTUBER
Content
By Elizabeth Klumpp Verified| Hematology Advisor Verified Combination treatment with acalabrutinib and axicabtagene ciloceucel (axi-cel) produced durable responses and was considered well tolerated in a phase 1/2 trial of patients with relapsed or refractory B-cell lymphoma. Results from this trial were presented at Tandem Meetings 2024. The trial (ClinicalTrials.gov Identifier: NCT04257578) included 18 patients who had diffuse large B-cell lymphoma (n=14), follicular lymphoma (n=3), or primary mediastinal B-cell lymphoma (n=1).
By Elizabeth Klumpp Verified| medicalbag.com@ New data appear to support earlier use of COVID-19 vaccines in patients who have received a hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. Researchers found that patients who were vaccinated 3-4 months after HSCT or CAR T-cell therapy had similar humoral and T-cell responses as patients who were vaccinated at 4-12 months after cellular therapy. The findings suggest “there’s not much benefit to waiting,” said Joshua A.
By Elizabeth Klumpp Verified| Hematology Advisor Verified Combination treatment with acalabrutinib and axicabtagene ciloceucel (axi-cel) produced durable responses and was considered well tolerated in a phase 1/2 trial of patients with relapsed or refractory B-cell lymphoma. Results from this trial were presented at Tandem Meetings 2024. The trial (ClinicalTrials.gov Identifier: NCT04257578) included 18 patients who had diffuse large B-cell lymphoma (n=14), follicular lymphoma (n=3), or primary mediastinal B-cell lymphoma (n=1).
Company Info
Haymarket Media
McMahons Point, New South Wales, Australia
+61 2 8399 7636